JPH0586380B2 - - Google Patents
Info
- Publication number
- JPH0586380B2 JPH0586380B2 JP8590744A JP9074485A JPH0586380B2 JP H0586380 B2 JPH0586380 B2 JP H0586380B2 JP 8590744 A JP8590744 A JP 8590744A JP 9074485 A JP9074485 A JP 9074485A JP H0586380 B2 JPH0586380 B2 JP H0586380B2
- Authority
- JP
- Japan
- Prior art keywords
- paramagnetic
- contrast agent
- agent according
- vesicles
- vesicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000005298 paramagnetic effect Effects 0.000 claims description 46
- 238000005481 NMR spectroscopy Methods 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 239000002872 contrast media Substances 0.000 claims description 33
- 150000002500 ions Chemical class 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 229910001868 water Inorganic materials 0.000 claims description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 19
- 239000000693 micelle Substances 0.000 claims description 11
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 239000002907 paramagnetic material Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 229910052691 Erbium Inorganic materials 0.000 claims description 2
- 229910052768 actinide Inorganic materials 0.000 claims description 2
- 150000001255 actinides Chemical class 0.000 claims description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 2
- 150000002602 lanthanoids Chemical class 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000005859 cell recognition Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 239000011651 chromium Substances 0.000 claims 1
- 229910017052 cobalt Inorganic materials 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 claims 1
- 229960003330 pentetic acid Drugs 0.000 description 23
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000003384 imaging method Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 16
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 12
- 239000011572 manganese Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002691 unilamellar liposome Substances 0.000 description 3
- 230000011713 vesicle targeting Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000004020 Brain Abscess Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 238000012565 NMR experiment Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- KILNVBDSWZSGLL-UHFFFAOYSA-O 2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-O 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Substances Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910021644 lanthanide ion Inorganic materials 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000010117 myocardial relaxation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- -1 nitroxides Chemical class 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60472184A | 1984-04-27 | 1984-04-27 | |
| US720954 | 1985-04-10 | ||
| US604721 | 1990-10-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60252429A JPS60252429A (ja) | 1985-12-13 |
| JPH0586380B2 true JPH0586380B2 (ko) | 1993-12-10 |
Family
ID=24420749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60090744A Granted JPS60252429A (ja) | 1984-04-27 | 1985-04-26 | Ｎｍｒイメージング用造影剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS60252429A (ko) |
| ZA (1) | ZA852979B (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999052505A1 (en) * | 1998-04-09 | 1999-10-21 | Nycomed Imaging A.S. | Use of particulate contrast agents in diagnostic imaging for studying physiological parameters |
| US6869591B2 (en) * | 2002-03-26 | 2005-03-22 | Barnes-Jewish Hospital | Paramagnetic particles that provide improved relaxivity |
| WO2007031910A2 (en) * | 2005-09-13 | 2007-03-22 | Philips Intellectual Property & Standards Gmbh | Multiple contrast agent injection for imaging |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
| JPS59139390A (ja) * | 1983-01-21 | 1984-08-10 | シェーリング・アクチエンゲゼルシャフト | 診断剤，その製法および錯塩 |
| JPS60100526A (ja) * | 1983-08-12 | 1985-06-04 | コンパニー オリ アンデュストリエ ソシエテ アノニム | 器官または病理用の特異的緩和剤 |
| JPS60179052A (ja) * | 1983-08-25 | 1985-09-12 | テクニケア・コ−ポレイシヨン | 生体組織の核磁気共鳴画像を増強する方法 |
-
1985
- 1985-04-22 ZA ZA852979A patent/ZA852979B/xx unknown
- 1985-04-26 JP JP60090744A patent/JPS60252429A/ja active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
| JPS59139390A (ja) * | 1983-01-21 | 1984-08-10 | シェーリング・アクチエンゲゼルシャフト | 診断剤，その製法および錯塩 |
| JPS60100526A (ja) * | 1983-08-12 | 1985-06-04 | コンパニー オリ アンデュストリエ ソシエテ アノニム | 器官または病理用の特異的緩和剤 |
| JPS60179052A (ja) * | 1983-08-25 | 1985-09-12 | テクニケア・コ−ポレイシヨン | 生体組織の核磁気共鳴画像を増強する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60252429A (ja) | 1985-12-13 |
| ZA852979B (en) | 1985-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920010391B1 (ko) | 핵자기 공명 조영제의 제조 방법 | |
| US7769423B2 (en) | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting | |
| Abou et al. | 89 Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer | |
| US6426058B1 (en) | Enhancement of NMR and MRI in the presence of hyperpolarized noble gases | |
| US5624662A (en) | Liposoluble heterocyclic compounds useful as magnetic resonance imaging agents | |
| US7672704B2 (en) | Methods and compositions for blood pool identification, drug distribution quantification and drug release verification | |
| US5458870A (en) | Compositions for magnetic resonance imaging using a manganese oxalate | |
| JPH04501723A (ja) | リポソーム性放射線造影剤 | |
| Cittadino et al. | In vivo magnetic resonance imaging detection of paramagnetic liposomes loaded with amphiphilic gadolinium (III) complexes: impact of molecular structure on relaxivity and excretion efficiency | |
| WO1998044910A1 (en) | NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO) | |
| JP2003530927A (ja) | 超分極化造影剤を用いた温度またはｐＨ値の生体内測定のためのＭＲ法 | |
| US4859450A (en) | Method of NMR imaging using antibody to cardiac myosin | |
| Ferrauto et al. | Chemical exchange saturation transfer (CEST) contrast agents | |
| JPH0586380B2 (ko) | ||
| WO1996010359A1 (en) | Chelate complex with high conspicuity for magnetic resonance imaging | |
| Miller et al. | Shift-reagent-aided 23Na NMR spectroscopy in cellular, tissue, and whole-organ systems | |
| CA2652264C (en) | Magnetic resonance contrast medium using polyethylene glycol and magnetic resonance image pick-up method | |
| Dias et al. | Contrast agents for nuclear magnetic resonance imaging | |
| Schroeter et al. | MRI | |
| Pereira et al. | Design and optimization of gadolinium based contrast agents for magnetic resonance imaging | |
| Wijesekera | Evaluating Hypoxia-Targeting Vectors for MRI Applications | |
| Cheng | Development of Mn (III) Porphyrins as High Relaxivity MRI Contrast Agents for Blood Pool and Targeted Imaging | |
| Aime et al. | Recent Developments of Contrast Agents, CEST and Low Fields | |
| NIESMAN | BA, Millikin University, 1980 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |